% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

hokiestock 13 posts  |  Last Activity: Jan 30, 2016 10:06 PM Member since: Jul 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hokiestock hokiestock Jan 30, 2016 10:06 PM Flag

    “In 2016, I hope that there will be significant progress in the treatment of brain tumors with hopefully positive trials of the EGFRvIII vaccine rindopepimut for newly diagnosed glioblastomas and checkpoint inhibitors for recurrent glioblastomas. 2016 will hopefully also see the launch of major Bayesian biomarker-driven adaptive design trials such as INSIGHT and GBM AGILE that will hopefully accelerate the development of new therapies for our patients.” – Dr. Patrick Wen, Dana-Farber Cancer Institute

  • Aduro and Celldex have almost identical charts over the last month. Seems to be a common theme driving down stocks with antibody and vaccine platforms. Sorrento is in same boat.
    23 trials now registered in EGFV111 for companies. Duke is doing Car-T EGFVv111 for glioblastoma. Seems Celldex started that trend. There appears to be too much literature any more around these mechanism of action around glio. Many of the other companies are trying to combine dual mechanism of action along with their EGFRV111. What appears to be the case is the market needs EGFRv111 mechanism of action and it will take years to find the right combo but anything is more than evident that Rindo needs to be approved to further development around glio and give confidence to others following steps. Rindo approval will only be the first step in cancer combination therapy for glioblastoma..

  • Celldex has checked in a lot of the current trials on going over the last 2 months. I expect a full 2016 report pretty soon. Noticed the Rindo study in newly diagnosed patients is probably ready for a glance around January. This below is one of the most important.

    I encourage everyone to visit who invests in biotech to check whats going on.

    A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
    This study is currently recruiting participants. (see Contacts and Locations)
    Verified November 2015 by Celldex Therapeutics
    Celldex Therapeutics
    Information provided by (Responsible Party):
    Celldex Therapeutics Identifier:
    First received: March 25, 2015
    Last updated: November 16, 2015
    Last verified: November 2015
    History of Changes

  • Reply to

    Combination therapy...

    by raysfrom98 Nov 20, 2015 3:35 PM
    hokiestock hokiestock Nov 20, 2015 8:28 PM Flag

    All of cancers have combination therapy but the unique thing is that the mechanism are no longer break you down and hope the body can recover. Actually the data is suggesting that BET Inhibitors are going to be synergistic with EGFRV111. Rintega and GPNMB have not even scratched the surface on their possible combinations. That is why many other companies are also exploring the EGFRV111 not EGFR but specifically the site where Rintega works.

    Epidermal growth factor receptor (EGFR) gene amplification and mutations are the most common oncogenic events in glioblastoma (GBM), but the mechanisms by which they promote aggressive tumor growth are not well understood. Here, through integrated epigenome and transcriptome analyses of cell lines, genotyped clinical samples, and TCGA data, we show that EGFR mutations remodel the activated enhancer landscape of GBM, promoting tumorigenesis through a SOX9 and FOXG1-dependent transcriptional regulatory network in vitro and in vivo. The most common EGFR mutation, EGFRvIII, sensitizes GBM cells to the BET-bromodomain inhibitor JQ1 in a SOX9, FOXG1-dependent manner. These results identify the role of transcriptional/epigenetic remodeling in EGFR-dependent pathogenesis and suggest a mechanistic basis for epigenetic therapy.

  • Kite looks like competition. PLK Inhibitors are showing some interesting model studies the last month or so. Maybe worth doing some research on Poli Like Kinase Inbhibitors.

  • Reply to

    Celldex EGFR info

    by hokiestock May 30, 2015 6:24 PM
    hokiestock hokiestock May 30, 2015 6:26 PM Flag

    Page 80

  • hokiestock by hokiestock May 30, 2015 6:24 PM Flag

    See around page 88 to 89

  • Reply to

    3BNC117 Making new this week.

    by hokiestock Apr 11, 2015 10:13 AM
    hokiestock hokiestock Apr 11, 2015 9:21 PM Flag

    3BNC117 was manufactured by Celldex Therapeutics in CHO cells and purified by chromatography and sterile filtration. All the mAb preparations were endotoxin free. Cocktails of mAbs or single mAbs were administered to monkeys once or twice by the intravenous route at a dose of 10 mg/kg for each mAb. Monkeys were bled up to three times per week for viral loads. Immunologic and virologic data were generated blinded. All animal studies were approved by the appropriate

    Institutional Animal Care and Use Committee (IACUC).

  • Reply to

    3BNC117 Making new this week.

    by hokiestock Apr 11, 2015 10:13 AM
    hokiestock hokiestock Apr 11, 2015 8:59 PM Flag

    Circulating precursors of human CD1c+ and CD141+ dendritic cells.
    Published in The Journal of experimental medicine, 2015-03-09, Volume 212
    Brigham and Women's Hospital, The Rockefeller University, Hospital for Special Surgery, Columbia University, Partners HealthCare, Celldex Therapeutics
    Gaëlle Breton, Jaeyop Lee, Yu Jerry Zhou, Joseph J Schreiber, Tibor Keler, Sarah Puhr, Niroshana Anandasabapathy, Sarah Schlesinger, Marina Caskey, Kang Liu, Michel C Nussenzweig
    Two subsets of conventional dendritic cells (cDCs) with distinct cell surface markers and functions exist in mouse and human. The two subsets of cDCs are specialized antigen-presenting cells that initiate T cell immunity and tolerance. In the mouse, a migratory cDC precursor (...
    Associated with:
    Brigham and Women's Hospital Brigham and Women's Hospital The Rockefeller University The Rockefeller University Hospital for Special Surgery Hospital for Special Surgery Columbia University Columbia University Partners HealthCare Partners HealthCare Celldex Therapeutics Celldex Therapeutics

  • Reply to

    3BNC117 Making new this week.

    by hokiestock Apr 11, 2015 10:13 AM
    hokiestock hokiestock Apr 11, 2015 5:19 PM Flag

  • Very interesting product showing destruction in almost 80% of HIV strains. Worth a Google. This is the Rockefeller product manufactured by Celldex.

  • Reply to

    Stocks to Consider

    by hokiestock Mar 20, 2015 8:55 PM
    hokiestock hokiestock Mar 21, 2015 10:33 AM Flag

    Its a tough call because we are in a major dynamic shift. Gild is making 4 billion a profit per quarter and they pay off that debt in a couple years who knows. CLDX has the most interesting dynamics and would be the one to go from 20 to 100 in a few months. That would mean Rindo approval and Gpnmb approved within next year. I think we see PD1 trials with Roche in triple negative as well. We are in a dynamic market and I think cancer will be a tough call in 10 years but mental illness is what cancer was 15 years ago. CLDX is always my number one pick but the big boys are very strong. Celg, Amgen, Novo, BMY and Roche but they could settle down. I want the next ALNY, ISIS and CLDX fits that bill but I want to diversify away from oncology. Actually XON could be the top dog of all in 5 years because they are a pure diversified company. I will probably go back and add Mack I had it at 3 and 4 and didn't keep enough of it or long enough. CLDN has the most potential to be go up 50 dollars in one day but be very careful.
    Alot of good companies and these companies are better at what they do than 15 years ago. Please share any picks, I am always interested in market dynamics and picks.

  • hokiestock by hokiestock Mar 20, 2015 8:55 PM Flag

    Please share your list: I keep a wide range of options from long term to disease state. 60 percent of drugs in research are in oncology:

    If anyone has any mental illness plays please share, mine are Roche and NERV you could throw in a Ludbeck but do not own.
    All of these companies are worth a few minutes of glancing at. CLDX since 4, Gave Celladon two years ago before IPO and XON before IPO. TKMR at 6 and ISIS at 12.
    Stock are more expensive now so be careful.

    Europe: Ablynx, Galapagos and CeRenis Therapeutics.
    5 or Under: Idera -Idra
    Generic Companies: Sagent Pharmaceuticals
    Rare Treatment: Rare Ultragenyx, (RARE), Fibrogen (FGEN)
    Expensive: Blue, Kite.
    Interesting and Expensive: Celladon, Esperion
    Good Entry Points: Achaogen, Vascular Biogenics, Aquinox, NovoNorDisk
    TOP Dog: Amgen, Roche, Gilead, Novo NorDisk,
    Possible Huge Years: Gild, CLDX, XON, TGTX,
    Great Science: Atra Atara Biosciences, Calitheria (CALA)
    Worth Looking; Five Prime Therapuetics, ISIS, BMY, SNY,
    Low dollar: APHB, SYN
    Best in show if clinical trials positive: CLDX
    Best Long Term: Amgen, Roche, GIld
    Tekmira, REgulus and Prothena all worth looking up.
    Best unknow sleepers: NERV, Addex therapeutics ( these are mental illness plays)

1.42-0.15(-9.55%)Feb 5 4:00 PMEST